Literature DB >> 21047676

Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma.

S-L Catherine Jin1, Sho Goya, Susumu Nakae, Dan Wang, Matthew Bruss, Chiaoyin Hou, Dale Umetsu, Marco Conti.   

Abstract

BACKGROUND: Cyclic AMP (cAMP) signaling modulates functions of inflammatory cells involved in the pathogenesis of asthma, and type 4 cAMP-specific phosphodiesterases (PDE4s) are essential components of this pathway. Induction of the PDE4 isoform PDE4B is necessary for Toll-like receptor signaling in monocytes and macrophages and is associated with T cell receptor/CD3 in T cells; however, its exact physiological function in the development of allergic asthma remains undefined.
OBJECTIVES: We investigated the role of PDE4B in the development of allergen-induced airway hyperresponsiveness (AHR) and T(H)2-driven inflammatory responses.
METHODS: Wild-type and PDE4B(-/-) mice were sensitized and challenged with ovalbumin and AHR measured in response to inhaled methacholine. Airway inflammation was characterized by analyzing leukocyte infiltration and cytokine accumulation in the airways. Ovalbumin-stimulated cell proliferation and T(H)2 cytokine production were determined in cultured bronchial lymph node cells.
RESULTS: Mice deficient in PDE4B do not develop AHR. This protective effect was associated with a significant decrease in eosinophils recruitment to the lungs and decreased T(H)2 cytokine levels in the bronchoalveolar lavage fluid. Defects in T-cell replication, T(H)2 cytokine production, and dendritic cell migration were evident in cells from the airway-draining lymph nodes. Conversely, accumulation of the T(H)1 cytokine IFN-γ was not affected in PDE4B(-/-) mice. Ablation of the orthologous PDE4 gene PDE4A has no impact on airway inflammation.
CONCLUSION: By relieving a cAMP-negative constraint, PDE4B plays an essential role in T(H)2-cell activation and dendritic cell recruitment during airway inflammation. These findings provide proof of concept that PDE4 inhibitors with PDE4B selectivity may have efficacy in asthma treatment.
Copyright © 2010 American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21047676      PMCID: PMC3002752          DOI: 10.1016/j.jaci.2010.08.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  50 in total

Review 1.  The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response.

Authors:  G M Kammer
Journal:  Immunol Today       Date:  1988 Jul-Aug

Review 2.  Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma.

Authors:  T J Torphy
Journal:  Trends Pharmacol Sci       Date:  1994-10       Impact factor: 14.819

3.  Differential regulation of IL 6, IL 1 A, IL 1 beta and TNF alpha production in LPS-stimulated human monocytes: role of cyclic AMP.

Authors:  S Bailly; B Ferrua; M Fay; M A Gougerot-Pocidalo
Journal:  Cytokine       Date:  1990-05       Impact factor: 3.861

4.  Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation.

Authors:  J E Souness; C M Carter; B K Diocee; G A Hassall; L J Wood; N C Turner
Journal:  Biochem Pharmacol       Date:  1991-07-25       Impact factor: 5.858

5.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

Authors:  D S Robinson; Q Hamid; S Ying; A Tsicopoulos; J Barkans; A M Bentley; C Corrigan; S R Durham; A B Kay
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

6.  Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes.

Authors:  B S Skålhegg; B F Landmark; S O Døskeland; V Hansson; T Lea; T Jahnsen
Journal:  J Biol Chem       Date:  1992-08-05       Impact factor: 5.157

7.  Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils.

Authors:  T Kaneko; R Alvarez; I F Ueki; J A Nadel
Journal:  Cell Signal       Date:  1995-07       Impact factor: 4.315

8.  IL-13 expression at the sites of allergen challenge in patients with asthma.

Authors:  S K Huang; H Q Xiao; J Kleine-Tebbe; G Paciotti; D G Marsh; L M Lichtenstein; M C Liu
Journal:  J Immunol       Date:  1995-09-01       Impact factor: 5.422

9.  Role of cyclic nucleotides and nitric oxide in blood mononuclear cell IgE production stimulated by IL-4.

Authors:  N Paul-Eugène; J Pène; J Bousquet; B Dugas
Journal:  Cytokine       Date:  1995-01       Impact factor: 3.861

10.  Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures.

Authors:  D A Lebman; R L Coffman
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  30 in total

Review 1.  Advances in targeting cyclic nucleotide phosphodiesterases.

Authors:  Donald H Maurice; Hengming Ke; Faiyaz Ahmad; Yousheng Wang; Jay Chung; Vincent C Manganiello
Journal:  Nat Rev Drug Discov       Date:  2014-04       Impact factor: 84.694

2.  Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi.

Authors:  Seiko Susuki-Miyata; Masanori Miyata; Byung-Cheol Lee; Haidong Xu; Hirofumi Kai; Chen Yan; Jian-Dong Li
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

Review 3.  Phosphodiesterase inhibitors as therapeutics for traumatic brain injury.

Authors:  David J Titus; Anthony A Oliva; Nicole M Wilson; Coleen M Atkins
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 4.  PDE4 as a target for cognition enhancement.

Authors:  Wito Richter; Frank S Menniti; Han-Ting Zhang; Marco Conti
Journal:  Expert Opin Ther Targets       Date:  2013-07-25       Impact factor: 6.902

5.  Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior.

Authors:  Rolf T Hansen; Marco Conti; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2014-02-22       Impact factor: 4.530

Review 6.  Asthma Pharmacogenomics: 2015 Update.

Authors:  Joshua S Davis; Scott T Weiss; Kelan G Tantisira
Journal:  Curr Allergy Asthma Rep       Date:  2015-07       Impact factor: 4.806

7.  In utero exposure to second-hand smoke aggravates adult responses to irritants: adult second-hand smoke.

Authors:  Rui Xiao; Zakia Perveen; Daniel Paulsen; Rodney Rouse; Namasivayam Ambalavanan; Michael Kearney; Arthur L Penn
Journal:  Am J Respir Cell Mol Biol       Date:  2012-09-06       Impact factor: 6.914

Review 8.  The pharmacogenetics and pharmacogenomics of asthma therapy.

Authors:  S M Tse; K Tantisira; S T Weiss
Journal:  Pharmacogenomics J       Date:  2011-10-11       Impact factor: 3.550

9.  A pathophysiological role of PDE3 in allergic airway inflammation.

Authors:  Jan Beute; Melanie Lukkes; Ewout P Koekoek; Hedwika Nastiti; Keerthana Ganesh; Marjolein Jw de Bruijn; Steve Hockman; Menno van Nimwegen; Gert-Jan Braunstahl; Louis Boon; Bart N Lambrecht; Vince C Manganiello; Rudi W Hendriks; Alex KleinJan
Journal:  JCI Insight       Date:  2018-01-25

10.  Discovery of triazines as selective PDE4B versus PDE4D inhibitors.

Authors:  Timothy J Hagen; Xuesheng Mo; Alex B Burgin; David Fox; Zheng Zhang; Mark E Gurney
Journal:  Bioorg Med Chem Lett       Date:  2014-06-12       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.